Institute for Pharmacological Research Mario Negri IRCCS, Ranica, BG, Italy.
IRCCS "Ca' Granda Maggiore Policlinico" Hospital Foundation, Milan, Italy.
Intern Emerg Med. 2020 Apr;15(3):357-359. doi: 10.1007/s11739-020-02293-4. Epub 2020 Mar 2.
Individuals may have conflicts of interest (CoI) when they choose between the duties of their jobs and their own private interests. In medicine, CoI are potentially ubiquitous and their disclosure has now become the most frequent strategy to address them in professional lives. In the medical literature, CoI are classified into two different types-financial and non-financial. Financial CoI are easy to identify and can bias any kind of results in research; so, their disclosure is very important. The unsolvable dilemma is where to set the lowest limit for sums received from industry. Non-financial CoI are a very large category intrinsically related to the individuals concerned, ranging from family relationships to religious beliefs, and the mere disclosure of many of them can raise privacy and ethical issues. Two opposite narratives characterize the debate on financial CoI caused by pharmaceutical industry. The critical side argues that, because the primary goal of pharmaceutical industry is inevitably to promote its products, the best strategy is to stay away from financial CoI. On the other hand, the defensive side claims that financial CoI are boosted by ideology but meaningless in real practice, since any kind of interest can raise a potential conflict. A missing point in the debate on financial CoI is that health care is a classical example of 'market failure' in the economic theory. Since health cannot be considered a 'consumer good', the economic paradigm of 'free market' does not fit for healthcare products. To conclude, even though transparency on financial CoI cannot itself deter the risk of bias, rejecting it would be an even bigger mistake. At variance, mandatory disclosure of non-financial CoI risks to be confusing and questionable in many cases, paradoxically distracting attention from the potential bias created by financial CoI.
个人在履行工作职责和追求自身私利时可能存在利益冲突(Conflict of Interest,CoI)。在医学领域,利益冲突可能无处不在,披露利益冲突已成为解决职业生活中利益冲突的最常见策略。在医学文献中,利益冲突分为财务利益冲突和非财务利益冲突两类。财务利益冲突易于识别,可能会影响研究的任何结果,因此披露财务利益冲突非常重要。但难以解决的困境在于,应将从行业获得的款项设定为多少金额时,才应被视为存在利益冲突。非财务利益冲突是一个非常大的类别,与个人密切相关,从家庭关系到宗教信仰不等,仅披露其中许多利益冲突就可能引发隐私和伦理问题。医药行业引发的财务利益冲突的争论存在两种截然相反的说法。批评观点认为,由于医药行业的首要目标不可避免地是推广其产品,因此最好的策略是远离财务利益冲突。另一方面,防御观点则声称,财务利益冲突是由意识形态推动的,但在实践中毫无意义,因为任何利益都可能引发潜在的冲突。财务利益冲突争论中缺失的一点是,医疗保健是经济理论中“市场失灵”的经典例子。由于健康不能被视为“消费品”,因此“自由市场”的经济模式并不适用于医疗保健产品。总之,即使财务利益冲突的透明度本身不能阻止偏见的风险,但拒绝披露则是更大的错误。相比之下,在许多情况下,强制性披露非财务利益冲突可能会令人困惑和值得怀疑,这反而会分散人们对财务利益冲突所造成的潜在偏见的注意力。